Alimentary pharmacology & therapeutics · 2001
What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Calvet X, Gené E, López T, Gisbert J P
Аннотация
BACKGROUND: Triple therapy with a proton pump inhibitor, clarithromycin and amoxicillin is widely used for H. pylori infection. The appropriate length of treatment remains controversial.
AIM: To determine whether length of treatment has an impact on the cost-effectiveness of triple therapy.
METHODS: The study took the form of a cost-effectiveness analysis spanning 2 years. The perspective was societal and the setting, ambulatory care. Subjects were Helicobacter pylori-positive patients with a duodenal ulcer. The triple therapy trials spanned 7, 10 or 14 days and the main outcome measures were cost per patient and marginal cost for additional cured patient calculated for a low cost-of-care setting (Spain), for a high-cost setting (USA), and for two follow-up strategies: (i) systematic 13C-urea breath test after eradication; (ii) clinical follow-up, breath-test if symptoms recurred.
RESULTS: Base-case analysis showed that for both the 13C-UBT and the clinical follow-up branches, lowest costs were obtained with 7-day schedules both in Spain and the USA. Sensitivity analysis showed that in Spain, 10-day therapies would have to increase 7-day cure rates by 10-12% to become cost-effective. In contrast, in the USA only a 3-5% increase was needed. The corresponding figures for 14-day therapy were 25-35% and 8-11%, respectively.
CONCLUSIONS: Seven-day therapies seem the most cost-effective strategy. However, in high-cost areas the differences were less evident.
AIM: To determine whether length of treatment has an impact on the cost-effectiveness of triple therapy.
METHODS: The study took the form of a cost-effectiveness analysis spanning 2 years. The perspective was societal and the setting, ambulatory care. Subjects were Helicobacter pylori-positive patients with a duodenal ulcer. The triple therapy trials spanned 7, 10 or 14 days and the main outcome measures were cost per patient and marginal cost for additional cured patient calculated for a low cost-of-care setting (Spain), for a high-cost setting (USA), and for two follow-up strategies: (i) systematic 13C-urea breath test after eradication; (ii) clinical follow-up, breath-test if symptoms recurred.
RESULTS: Base-case analysis showed that for both the 13C-UBT and the clinical follow-up branches, lowest costs were obtained with 7-day schedules both in Spain and the USA. Sensitivity analysis showed that in Spain, 10-day therapies would have to increase 7-day cure rates by 10-12% to become cost-effective. In contrast, in the USA only a 3-5% increase was needed. The corresponding figures for 14-day therapy were 25-35% and 8-11%, respectively.
CONCLUSIONS: Seven-day therapies seem the most cost-effective strategy. However, in high-cost areas the differences were less evident.
Предметные рубрики MeSH
AmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsBreath TestsCarbon IsotopesClarithromycinCost-Benefit AnalysisDecision Support TechniquesDrug Administration ScheduleDrug CostsDuodenal UlcerHelicobacter InfectionsHelicobacter pyloriHumansPenicillinsProton Pump InhibitorsProton PumpsTreatment OutcomeUrea